Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in <scp>EMPEROR‐Reduced</scp>Faı̈ez Zannad, Milton Packer, Stefan D. Anker et al.|European Journal of Heart Failure|2022Cited by 44
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPA‐REG OUTCOME</scp> trialChristoph Wanner, Silvio E. Inzucchi, Bernard Zinman et al.|Diabetes Obesity and Metabolism|2020Cited by 36
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetesBernhard K. Krämer, Christoph Wanner, Sibylle J. Hauske et al.|Journal of Diabetes and its Complications|2023Cited by 6
248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME TrialSilvio E. Inzucchi, Sibylle J. Hauske, Bernard Zinman et al.|Diabetes|2019Cited by 0
Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR Heart Failure TrialsFaı̈ez Zannad, Milton Packer, Stefan D. Anker et al.|Journal of the American Society of Nephrology|2021Cited by 0